Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DENV-4-LVHC (Dengue-4-Virus-Live Virus Human Challenge) is a weakened form of an experimental dengue virus serotype 4 (DENV-4) strain, specifically H-241, utilized in human challenge studies. Its primary purpose is to safely induce a controlled, mild-to-moderate dengue infection in healthy adult volunteers. This model serves as a critical tool in the development and evaluation of dengue vaccines and therapeutics, allowing researchers to assess the safety, optimal dose, and protective efficacy of investigational products against dengue fever. The challenge virus aims to elicit symptoms consistent with self-limited dengue, enabling the study of viral-host immunology in a controlled setting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DENV-4-LVHC.